Compositions and methods of use for osteoclast inhibitor factors
    2.
    发明授权
    Compositions and methods of use for osteoclast inhibitor factors 失效
    破骨细胞抑制因子的组合物和使用方法

    公开(公告)号:US5985832A

    公开(公告)日:1999-11-16

    申请号:US139424

    申请日:1998-08-25

    摘要: It has been found that two proteins produced by human osteoclasts inhibit osteoclast formation in bone marrow cultures and inhibit bone resorption in a fetal long bone assay. One of the proteins is identical to an Ly6 gene family protein and homologous to the Sca2 antigen, Ly6A. The second, OIP-2, is a novel protein not previously identified. The discovery of the osteoclast inhibition property of the OIP proteins suggests the therapeutic potential for patients with disordered osteoclast activity in such conditions as osteoporosis.

    摘要翻译: 已经发现,人类破骨细胞产生的两种蛋白质在骨髓培养物中抑制破骨细胞形成,并在胎儿长骨测定中抑制骨吸收。 其中一种蛋白质与Ly6基因家族蛋白质相同,与Sca2抗原Ly6A同源。 第二个,OIP-2是一种未经鉴定的新蛋白。 发现OIP蛋白质的破骨细胞抑制性质表明在诸如骨质疏松症的病症中具有无序破骨细胞活性的患者的治疗潜力。